The two scientists won the European Inventor Award jointly in the SMEs category from the European Patent Office (EPO) for their vaccine assembly platform, the office announced on Tuesday.
The vaccine could be used to treat different types of cancer, boosting the immune system’s response to the disease and offering new hope for cancer treatment, the EPO saidExternal link.
“Derouazi and Belnoue’s invention assembles three essential components of a vaccine into a single protein [……] to produce vaccines for different types of cancer. They are intended for use alongside treatments such as surgery, chemotherapy and radiotherapy,” the EPO said.
The KISIMA platform was first used to produce a vaccine designed to treat metastatic colorectal cancer, and early-stage human trials are underway.
Derouazi studied biology and biotechnology in Geneva, Berlin and Lausanne before completing a post-doc at the French National Center for Scientific Research in Paris.
Launched in 2006, the award, which is attributed in five different categories, honours individuals and team solutions to some of the biggest challenges, the EPO said.
Swisscom records over 200 million cyberattacks per month
This content was published on
Swiss state-owned telecommunications provider Swisscom has to defend against 200 million cyberattacks on its own infrastructure every month.
This content was published on
International Women's Rights Day saw some 4,800 demonstrators march in the Swiss cities of Lausanne and Geneva on Saturday.
Diversity and equality ‘under threat’: ex-Swiss minister
This content was published on
Dismantling diversity programmes is a backwards step for equality, warns former Swiss government minister Simonetta Sommaruga.
Swiss regulator fines US bank Citi over fat-finger crash
This content was published on
Citigroup fined CHF500,000 by Swiss stock exchange regulator after a fat-finger trade caused a 2022 flash crash in European stocks.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.